Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript Summary
Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript Summary
Non-GAAP recurring The following is a summary of the Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript:
以下是jaguar health公司（JAGX）2024年第三季度业绩会的摘要：
Financial Performance:
财务表现：
Jaguar Health reported Q3 2024 revenue of approximately $3.1 million, a 14% increase from Q2 2024 and an 11% increase from Q3 2023.
Net loss from operations decreased by $1.5 million compared to the previous year from $8.8 million in Q3 2023 to $7.3 million in Q3 2024.
Non-GAAP recurring EBITDA for Q3 2024 was a net loss of $9.2 million, worsening from a loss of $6.2 million in Q3 2023.
jaguar health报告2024年第三季度的营业收入约为310万，较2024年第二季度增长14%，较2023年第三季度增长11%。
与去年相比，运营净亏损减少了150万，从2023年第三季度的880万降至2024年第三季度的730万。
2024年第三季度的非公认会计原则（Non-GAAP）经常性EBITDA净亏损为920万，较2023年第三季度的620万亏损恶化。
Business Progress:
业务进展：
Launched FDA-approved oral mucositis prescription product, Gelclair, expanding Jaguar's commercialized products.
Achieved significant milestones in clinical development, particularly with the OnTarget Phase III trial in breast and lung cancer patients.
Continued progress with crofelemer for rare diseases, focusing on two Phase II trials for congenital diarrheal disorders and short bowel syndrome with intestinal failure.
推出了FDA批准的口服黏膜炎处方产品Gelclair，扩展了jaguar的商业化产品。
在临床开发中取得了重大里程碑，特别是在针对乳腺癌和肺癌患者的OnTarget第三阶段试验中。
对于罕见疾病，继续推进crofelemer的研究，重点是针对先天性腹泻障碍和肠功能不全的短肠综合征的两项二期临床试验。
Opportunities:
机会：
Entered the supportive care market for cancer treatment side effects with new products like Gelclair for oral mucositis, addressing significant unmet medical needs.
Potential revenue growth through clinical trials in Europe and the MENA regions for microvillus inclusion disease and short bowel syndrome.
进入癌症治疗副作用的支持性护理市场，推出了新产品如Gelclair用于口腔黏膜炎，解决了重大的医疗未满足需求。
通过在欧洲和中东及北非地区进行微绒毛包涵病和短肠综合征的临床试验，可能实现营业收入增长。
Risks:
风险：
Financial performance shows increasing losses year-over-year, highlighting challenges in reaching profitability.
Clinical trials, particularly for cancer therapy-related diarrhea, face uncertainties in achieving primary endpoints, which may impact regulatory approval and market acceptance.
财务表现显示逐年亏损增加，突显出实现盈利的挑战。
临床试验，特别是针对癌症治疗相关腹泻的试验，面临达到主要终点的不确定性，这可能影响监管审批和市场接受度。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。内容准确性无法完全保证。如需更全面详情，请参阅IR网站。本文仅供投资者参考，不具有任何指导或推荐建议。
